{"id":"W3175939027","doi":"10.1016/s1368-8375(21)00375-4","title":"P-88 First-Line Pembrolizumab With or Without Lenvatinib in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Phase 3 LEAP-010 Study","year":2021,"lang":"en","type":"article","venue":"Oral Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Pembrolizumab; Lenvatinib; Head and neck squamous-cell carcinoma; Medicine; Oncology; Internal medicine; Head and neck cancer; Basal cell; Head and neck; Phases of clinical research; Cancer research; Cancer; Immunotherapy; Chemotherapy; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001130776,0.001147904,0.001810937,0.0004096751,0.0003445502,0.001185344,0.001007134,0.0009224236,0.003318352],"category_scores_gemma":[0.0005042379,0.0005580026,0.001578059,0.0003449219,0.0008202685,0.001174492,0.0003582713,0.003574391,0.001122162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001398237,"about_ca_system_score_gemma":0.001349709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002014881,"about_ca_topic_score_gemma":0.006684744,"domain_scores_codex":[0.9997028,0.00009564507,0.00001104553,0.00006475268,0.00003530262,0.00009043143],"domain_scores_gemma":[0.9997352,0.00004224417,0.00004102078,0.00002570563,0.00002045653,0.0001354101],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5610183,0.07120406,0.01115586,0.002733528,0.004775333,0.000387755,0.0005594461,0.005128135,0.05174719,0.0006824441,0.012317,0.2782909],"study_design_scores_gemma":[0.5263748,0.4270581,0.02601723,0.000146527,0.002525559,0.000675136,0.0002199496,0.002795198,0.006781424,0.0003866191,0.006953117,0.00006640737],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923514,0.003062411,0.0002540276,0.0003718596,0.0001205288,0.0007575525,0.0009103148,0.00008544719,0.002086578],"genre_scores_gemma":[0.9864134,0.00387378,0.0009163503,0.0009468126,0.000119216,0.0010498,0.002115682,0.00003982688,0.004525226],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003318352,"threshold_uncertainty_score":0.01110095,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05775824172927307,"score_gpt":0.3728306085500255,"score_spread":0.3150723668207525,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}